文献速递白血病淋巴瘤

在成人前体B细胞急性淋巴细胞白血病标准诱导化疗中加用四剂利妥昔单抗(UKALL14):一项3期多中心随机对照试验

Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.
PubMed 文献 · Lancet Haematol · 2022-01-01

UKALL14研究在65个中心纳入586例25-65岁新发BCR-ABL1阴性或19-65岁BCR-ABL1阳性前体B细胞急性淋巴细胞白血病成人患者,1:1随机接受标准诱导化疗或标准诱导化疗加四剂利妥昔单抗(375 mg/m2,第3、10、17、24天)。中位随访53.7个月,3年无事件生存率标准组43.7% vs 利妥昔单抗组51.4%(HR 0.85,95%CI 0.69-1.06;p=0.14),未显著改善。

要点

  • 标准诱导化疗加四剂利妥昔单抗未显著改善3年无事件生存(43.7% vs 51.4%,HR 0.85,p=0.14)。
  • 两组不良事件率无差异,诱导1-2期致死性(5级)事件标准组11例(4%)vs 利妥昔单抗组13例(5%)。
  • 作者认为利妥昔单抗在急性淋巴细胞白血病中有益,但诱导期四剂可能不足。

核心结论

  • 标准诱导化疗加四剂利妥昔单抗较标准诱导化疗未显著改善无事件生存。
  • 作者认为利妥昔单抗在急性淋巴细胞白血病中有益,但诱导期四剂可能不足。

研究设计与样本

  • 研究者发起的3期多中心随机对照试验,在英国所有治疗急性淋巴细胞白血病的国民健康服务中心(65个中心)进行。
  • 纳入25-65岁新发BCR-ABL1阴性或19-65岁BCR-ABL1阳性前体B细胞急性淋巴细胞白血病成人患者。
  • 586例患者1:1随机分配至标准诱导化疗(n=292)或标准诱导化疗加四剂利妥昔单抗(n=294),采用最小化法随机并按性别、年龄和白细胞计数分层。
  • 利妥昔单抗375 mg/m2静脉给药,第3、10、17、24天各一剂;患者、临床医生和工作人员(包括试验统计师)未设盲,但分析微小残留病和CD20的中心实验室对治疗分配设盲。
  • 主要终点为意向治疗人群的无事件生存;安全性在所有开始试验治疗的患者中评估;因误诊排除9例(标准组4例,利妥昔单抗组5例)。

主要发现

  • 中位随访53.7个月(IQR 40.3-70.4),3年无事件生存率标准组43.7%(95%CI 37.8-49.5)vs 利妥昔单抗组51.4%(95%CI 45.4-57.1),HR 0.85(95%CI 0.69-1.06),p=0.14。
  • 最常见不良事件为感染和血细胞减少,两组不良事件率无差异。
  • 诱导1-2期致死性(5级)事件标准组11例(4%)vs 利妥昔单抗组13例(5%)。
  • 3年非复发死亡率标准组23.7%(95%CI 19.0-29.4)vs 利妥昔单抗组20.6%(95%CI 16.2-25.9),HR 0.88(95%CI 0.62-1.26),p=0.49。

关键数值与推荐

  • 利妥昔单抗剂量为375 mg/m2静脉给药,第3、10、17、24天各一剂。
  • 3年无事件生存率标准组43.7%(95%CI 37.8-49.5)vs 利妥昔单抗组51.4%(95%CI 45.4-57.1),HR 0.85(95%CI 0.69-1.06),p=0.14。
  • 3年非复发死亡率标准组23.7%(95%CI 19.0-29.4)vs 利妥昔单抗组20.6%(95%CI 16.2-25.9),HR 0.88(95%CI 0.62-1.26),p=0.49。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment for adults with acute lymphoblastic leukaemia requires improvement. UKALL14 was a UK National Cancer Research Institute Adult ALL group study that aimed to determine the benefit of adding the anti-CD20 monoclonal antibody, rituximab, to the therapy of adults with de novo B-precursor acute lymphoblastic leukaemia. METHODS: This was an investigator-initiated, phase 3, randomised controlled trial done in all UK National Health Service Centres treating patients with acute lymphoblastic leukaemia (65 centres). Patients were aged 25-65 years with de-novo BCR-ABL1-negative acute lymphoblastic leukaemia. Patients with de-novo BCR-ABL1-positive acute lymphoblastic leukaemia were eligible if they were aged 19-65 years. Participants were randomly assigned (1:1) to standard-of-care induction therapy or standard-of-care induction therapy plus four doses of intravenous rituximab (375 mg/m2 on days 3, 10, 17, and 24). Randomisation used minimisation and was stratified by sex, age, and white blood cell count. No masking was used for patients, clinicians, or staff (including the trial statistician), although the central laboratory analysing minimal residual disease and CD20 was masked to treatment allocation. The primary endpoint was event-free survival in the intention-to-treat population. Safety was assessed in all participants who started trial treatment. This study is registered with ClincialTrials.gov, NCT01085617. FINDINGS: Between April 19, 2012, and July 10, 2017, 586 patients were randomly assigned to standard of care (n=292) or standard of care plus rituximab (n=294). Nine patients were excluded from the final analysis due to misdiagnosis (standard of care n=4, standard of care plus rituximab n=5). In the standard-of-care group, median age was 45 years (IQR 22-65), 159 (55%) of 292 participants were male, 128 (44%) were female, one (<1%) was intersex, and 143 (59%) of 244 participants had high-risk cytogenetics. In the standard-of-care plus rituximab group, median age was 46 years (IQR 23-65), 159 (55%) of 294 participants were male, 130 (45%) were female, and 140 (60%) of 235 participants had high-risk cytogenetics. After a median follow-up of 53·7 months (IQR 40·3-70·4), 3-year event-free survival was 43·7% (95% CI 37·8-49·5) for standard of care versus 51·4% (45·4-57·1) for standard of care plus rituximab (hazard ratio [HR] 0·85 [95% CI 0·69-1·06]; p=0·14). The most common adverse events were infections and cytopenias, with no difference between the groups in the rates of adverse events. There were 11 (4%) fatal (grade 5) events in induction phases 1 and 2 in the standard-of-care group and 13 (5%) events in the standard-of-care plus rituximab group). 3-year non-relapse mortality was 23·7% (95% CI 19·0-29·4) in the standard-of-care group versus 20·6% (16·2-25·9) in the standard-of-care plus rituximab group (HR 0·88 [95% CI 0·62-1·26]; p=0·49). INTERPRETATION: Standard of care plus four doses of rituximab did not significantly improve event-free survival over standard of care. Rituximab is beneficial in acute lymphoblastic leukaemia but four doses during induction is likely to be insufficient. FUNDING: Cancer Research UK and Blood Cancer UK.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Marks DI, Kirkwood AA, Rowntree CJ, et al. Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial. Lancet Haematol. 2022. PMID: 35358441. doi:10.1016/S2352-3026(22)00038-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。